Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.
about
Neuroprotection in a novel mouse model of multiple sclerosisFree serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosisAnalysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory.Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1βAxonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosisNeuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.Serum neurofilament is associated with progression of brain atrophy and disability in early MS.Outcome measurement in neurodegenerative disease: attributes, applications & interpretation.The influence of sodium on pathophysiology of multiple sclerosis.Experimental autoimmune encephalomyelitis from a tissue energy perspective.Fluid biomarker and electrophysiological outcome measures for progressive MS trials.Science is 1% inspiration and 99% biomarkers.Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis studyThe only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level—NOALS Yeast Models—Past Success Stories and New Opportunities
P2860
Q27302918-5C2F7978-165F-4CF4-839D-362449BCD79DQ28586716-D59F95A5-C7D2-4EFC-B046-D11AF4F49717Q33692762-6A5A9A1A-058A-451B-B8B2-64A9BA1CA1F7Q33846630-BF3D8B42-8230-4473-8BF2-3E87927E26B7Q34570124-5B880FE4-8C32-4B10-A244-E6E70EB7079AQ36161527-9EB21E59-7CC6-4C29-A524-3B409E497AC2Q36562595-2F517A19-6F4B-4427-914D-1AAF3D2FE2CBQ38299472-77043728-E44C-4BA9-8F61-07FF132529BAQ38381437-DDD2BEDD-0112-418B-9595-E42A0C594069Q38570993-771517D9-5994-4A27-BA78-223CA14A1930Q39081430-B7FCB1CF-95F4-49CB-80DE-F347C8B40318Q46255661-973C2789-8E13-4B19-90CD-0AF8A12CA3B4Q47638443-796F5C09-2F1B-484B-913E-7AB2DD644056Q50984144-2E99A0AA-E580-447B-AE70-2E432F453980Q53212006-CADA60F3-067E-451D-A5F6-E7E0B419A986Q57161829-5B3A61F1-9AC3-4E61-9350-22E60AD4EC45Q57601807-FFB7D927-96CA-4198-848E-142A334255EBQ58698109-59AE3D20-AB04-493E-B6E4-9BDFC090F720
P2860
Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Biomarker report from the phas ...... rogate of disease progression.
@ast
Biomarker report from the phas ...... rogate of disease progression.
@en
Biomarker report from the phas ...... rogate of disease progression.
@nl
type
label
Biomarker report from the phas ...... rogate of disease progression.
@ast
Biomarker report from the phas ...... rogate of disease progression.
@en
Biomarker report from the phas ...... rogate of disease progression.
@nl
prefLabel
Biomarker report from the phas ...... rogate of disease progression.
@ast
Biomarker report from the phas ...... rogate of disease progression.
@en
Biomarker report from the phas ...... rogate of disease progression.
@nl
P2093
P2860
P50
P1433
P1476
Biomarker report from the phas ...... rogate of disease progression.
@en
P2093
David H Miller
Donna Grant
Julian Furby
Raj Kapoor
Robert Brenner
Sharmilee Gnanapavan
Steve Morant
Tom Hayton
Valerio Leoni
P2860
P304
P356
10.1371/JOURNAL.PONE.0070019
P407
P577
2013-08-01T00:00:00Z